ID

14959

Beskrivning

Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT01444716

Länk

https://clinicaltrials.gov/show/NCT01444716

Nyckelord

  1. 2016-05-09 2016-05-09 -
Uppladdad den

9 maj 2016

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Advanced Cancers NCT01444716

Eligibility Advanced Cancers NCT01444716

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
Beskrivning

chronic lymphocytic leukemia

Datatyp

boolean

Alias
UMLS CUI [1]
C0023434
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
Beskrivning

ecog

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
Beskrivning

adequate renal and hepatic function

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0232804
UMLS CUI [1,2]
C0232741
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
Beskrivning

prolymphocytic leukemia

Datatyp

boolean

Alias
UMLS CUI [1]
C0023486
known positivity for hiv
Beskrivning

hiv

Datatyp

boolean

Alias
UMLS CUI [1]
C0019682
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
Beskrivning

hepatitis b

Datatyp

boolean

Alias
UMLS CUI [1]
C0019163
prior treatment for chronic lymphocytic leukemia
Beskrivning

chronic lymphocytic leukemia

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0023434
UMLS CUI [1,2]
C1514463
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
Beskrivning

concurrent chemotherapy

Datatyp

boolean

Alias
UMLS CUI [1]
C3178775
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
Beskrivning

Protocol Compliance

Datatyp

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0009488
any known hypersensitivity to ofatumumab or its components.
Beskrivning

any known hypersensitivity to ofatumumab or its components.

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C1832027

Similar models

Eligibility Advanced Cancers NCT01444716

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
chronic lymphocytic leukemia
Item
patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.
boolean
C0023434 (UMLS CUI [1])
ecog
Item
the eastern cooperative oncology group (ecog)/world health organization (who) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ecog/who performance status of 0-1 and a cirs or charlson co-morbidity score of 2 or higher.
boolean
C1520224 (UMLS CUI [1])
adequate renal and hepatic function
Item
adequate renal and hepatic function (creatinine <2mg/dl and egfr more than 30cc/minute, bilirubin <2mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. patients with gilbert's syndrome are eligible.
boolean
C0232804 (UMLS CUI [1,1])
C0232741 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
prolymphocytic leukemia
Item
patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).
boolean
C0023486 (UMLS CUI [1])
hiv
Item
known positivity for hiv
boolean
C0019682 (UMLS CUI [1])
hepatitis b
Item
hepatitis b (hb) defined as a positive test for hbsag. in addition, if negative for hgsag but hbcab positive (regardless of hbsab status), a hb dna test will be performed and if positive the subject will be excluded.
boolean
C0019163 (UMLS CUI [1])
chronic lymphocytic leukemia
Item
prior treatment for chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
concurrent chemotherapy
Item
concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. localized radiotherapy to an area not compromising bone marrow function does not apply. patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.
boolean
C3178775 (UMLS CUI [1])
Protocol Compliance
Item
any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
any known hypersensitivity to ofatumumab or its components.
Item
any known hypersensitivity to ofatumumab or its components.
boolean
C0020517 (UMLS CUI [1,1])
C1832027 (UMLS CUI [1,2])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial